Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule

Witek, Małgorzata A.; Aufforth, Rachel; Wang, Hong; Kamande, Joyce W.; Jackson, Joshua M.; Pullagurla, Swathi R.; Hupert, Mateusz L.; Usary, Jerry; Wysham, Weiya Z.; Hilliard, Dawud; Montgomery, Stephanie A.; Bae‐Jump, Victoria L.; Carey, Lisa A.; Gehrig, Paola A.; Milowsky, Matthew I.; Perou, Charles M.; Soper, John T.; Whang, Young E.; Yeh, Jen Jen; Martin, George George; Soper, Steven A.

doi:10.1038/s41698-017-0028-8

Cited by 32 publications

(81 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36 The most recent research has documented, however, the presence of clinically relevant CTCs that express low levels of or do not express EpCAM, namely those with mesenchymal or stem cell characteristics. 28,29 Thus, a number of additional markers in addition to EpCAM, including N-Cadherin, O-Cadherin, VCAM-1, ICAM-1, CEA, hMUC1, EphB4, CD44, CD133, CD146, PSMA, HER2, EGFR, TROP-2, and FAPα have been explored for CTC selection. 28,29,37–41 Some of these markers lack specificity due to expression on normal blood cells, benign cells, and/or endothelial cells, while other markers are co-expressed with EpCAM and thereby provide little additional benefit to the assay.…”

Section: Properties Of Ctcsmentioning

confidence: 99%

“…28,29 Thus, a number of additional markers in addition to EpCAM, including N-Cadherin, O-Cadherin, VCAM-1, ICAM-1, CEA, hMUC1, EphB4, CD44, CD133, CD146, PSMA, HER2, EGFR, TROP-2, and FAPα have been explored for CTC selection. 28,29,37–41 Some of these markers lack specificity due to expression on normal blood cells, benign cells, and/or endothelial cells, while other markers are co-expressed with EpCAM and thereby provide little additional benefit to the assay. 40,42,43 Other markers are specific for a certain cancer type, such as the prostate specific membrane antigen (PSMA) for prostate cancer.…”

Section: Properties Of Ctcsmentioning

confidence: 99%

“…40,42,43 Other markers are specific for a certain cancer type, such as the prostate specific membrane antigen (PSMA) for prostate cancer. 29 …”

Section: Properties Of Ctcsmentioning

confidence: 99%

“…Using the sinusoidal microfluidic device (discussed below), the authors detected CTCs in 100% of patients with ovarian, colorectal, prostate, and pancreatic cancers and 80% of breast cancer patients. 29 Such results strongly suggest that assays exclusively selecting EpCAM(+) CTCs are not adequate.…”

Section: Properties Of Ctcsmentioning

confidence: 99%

“…34 Most critically, the self-referencing method could be used to determine recovery of patient-derived CTCs in clinical samples without prior knowledge of CTC abundance. 29 …”

Section: Properties Of Ctcsmentioning

confidence: 99%

See 4 more Smart Citations

Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells

et al. 2017

Self Cite

View full text Add to dashboard Cite

We present a critical review of microfluidic technologies and material effects on the analyses of circulating tumour cells (CTCs) selected from the peripheral blood of cancer patients. CTCs are a minimally invasive source of clinical information that can be used to prognose patient outcome, monitor minimal residual disease, assess tumour resistance to therapeutic agents, and potentially screen individuals for the early diagnosis of cancer. The performance of CTC isolation technologies depends on microfluidic architectures, the underyling principles of isolation, and the choice of materials. In this review, we present a critical review of the fundamental principles used in these technologies and discuss their performance. We also give context to how CTC isolation technologies enable downstream analysis of selected CTCs in terms of detecting genetic mutations and gene expression that could be used to gain information that may affect patient outcome.

show abstract

Section: Properties Of Ctcsmentioning

confidence: 99%

Section: Properties Of Ctcsmentioning

confidence: 99%

“…40,42,43 Other markers are specific for a certain cancer type, such as the prostate specific membrane antigen (PSMA) for prostate cancer. 29 …”

Section: Properties Of Ctcsmentioning

confidence: 99%

Section: Properties Of Ctcsmentioning

confidence: 99%

“…34 Most critically, the self-referencing method could be used to determine recovery of patient-derived CTCs in clinical samples without prior knowledge of CTC abundance. 29 …”

Section: Properties Of Ctcsmentioning

confidence: 99%

See 3 more Smart Citations

Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Circulating tumor cell profiling for precision oncology

Labib

2021

Molecular Oncology

View full text Add to dashboard Cite

Analysis of circulating tumor cells (CTCs) collected from patient's blood offers a broad range of opportunities in the field of precision oncology. With new advances in profiling technology, it is now possible to demonstrate an association between the molecular profiles of CTCs and tumor response to therapy. In this Review, we discuss mechanisms of tumor resistance to therapy and their link to phenotypic and genotypic properties of CTCs. We summarize key technologies used to isolate and analyze CTCs and discuss recent clinical studies that examined CTCs for genomic and proteomic predictors of responsiveness to therapy. We also point out current limitations that still hamper the implementation of CTCs into clinical practice. We finally reflect on how these shortcomings can be addressed with the likely contribution of multiparametric approaches and advanced data analytics.

show abstract

Smart Material‐Integrated Systems for Isolation and Profiling of Rare Cancer Cells and Emboli

Sagdic

İnci

2021

Adv Eng Mater

View full text Add to dashboard Cite

This review presents a broad aspect of smart material‐integrated systems for isolating and profiling rare circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) to provide physiological, biological, and mechanistic insights into cancer research. In particular, CTCs/CTM have emanated as essential pieces of evidence that can reveal clonal evolution, tumor heterogeneity, and disease progression within the metastatic cascade. Morphologies, cellular compositions, and rarity of CTCs/CTM make them difficult to track and isolate for profiling distinct molecular characteristics in the case of metastatic potential. Accordingly, with the advanced‐characterization techniques, examining the aspects of the specific surface markers of CTCs/CTM, epithelial‐to‐mesenchymal (EMT), mesenchymal‐to‐epithelial (MET) transitions, and timing of tumor cell dissemination would assist us to understand cancer biology and metastatic characteristics. Existing clinical and research methods for the enrichment and isolation of these sporadic cells depend on mainly conventional methods with low‐yield and expensive features. Owing to their specialized functions and analytical performances, smart material‐based technologies hold an enormous impact not only on cell detection, but also on cell isolation for downstream analyses. Herein, the main reasons for cell isolation are discussed and the recent developments in CTCs/CTM approaches for identifying further methods and future perspectives are elaborated on.

show abstract

Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule

Cited by 32 publications

References 41 publications

Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells

Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells

Circulating tumor cell profiling for precision oncology

Smart Material‐Integrated Systems for Isolation and Profiling of Rare Cancer Cells and Emboli

Contact Info

Product

Resources

About